Altimmune announces positive lean mass preservation data for pemvidutide and reports fourth quarter and full year 2023 financial results

Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass enrollment ongoing in impact phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (mash), with topline 24-week data expected q1 2025 preclinical study results showed a direct anti-fibrotic effect of pemvidutide in a non-steatotic model of liver fibrosis cash, cash equivalents and short-term investments of $198.0 million at december 31, 2023 webcast to be held today, march 27, 2024, at 8:30 am et gaithersburg, md., march 27, 2024 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended december 31, 2023, and provided a business update.
ALT Ratings Summary
ALT Quant Ranking